Peripheral nerve transmission L2 Flashcards
(45 cards)
How is ACh release modulated?
ACh release is physiologically regulated by mediators, including ACh itself, acting on pre-synaptic receptors.
At postganglionic parasympathetic nerve endings, inhibitory muscarinic M2 receptors participate in auto inhibition of ACh release;
other mediators, such as noradrenaline (NA), also inhibit the release of ACh.
At the NMJs, on the other hand, pre-synaptic nicotinic receptors (nAChRs) facilitate ACh release, a mechanism that may allow the synapse to function reliably during prolonged high-frequency activity.
what does atropine inhibit?
muscarine
what doesmtubocurarine inhibt?
nicotine
are nAChRs ion channels?
yep
A functional nAChR is a pentamer consisting of …
A functional nAChR is a pentamer consisting of a, b, g, d and e subunits with at least 2a subunits present.
how many ACh are required to open the channel?
2
Most nAChR isoforms are permeable to ….. whilst one of the CNS isoforms namely the (a7)5 channel, is highly …..permeable.
Most nAChR isoforms are permeable to Na+ and K+ whilst one of the CNS isoforms namely the (a7)5 channel, is highly Ca2+ permeable.
how are mAChRs classified?
M2 /M4 receptors -> typically present pre-synaptically -> inhibit neurotransmitter (including ACh itself) release

Within the synaptic or junctional cleft, most of the ACh is rapidly hydrolyzed into choline and acetate by acetylcholine esterase (AChE) which is located where?
Within the synaptic or junctional cleft, most of the ACh is rapidly hydrolyzed into choline and acetate by acetylcholine esterase (AChE) which is tethered to the post-synaptic membrane.
A ‘soluble’ AChE is present in…..
A ‘soluble’ AChE is present in the cytoplasm of the pre-synaptic nerve but understandably it doesn’t affect the life span of the released AChE.
As mentioned before, (α3)2(β2)3 represents the predominant Nn nAChR receptor variant. These channels are insensitive to _______ but are inhibited by _______ (a competitive antagonists) and ______ (you may use it during a practical).
As mentioned before, (α3)2(β2)3 represents the predominant Nn receptor variant. These channels are insensitive to α-bungarotoxin but are inhibited by trimetaphan (a competitive antagonists) and hexamethonium (you may use it during a practical).
label the post ganglionic membrane potential changes


ganglionic stimulants:
gieve some Nn receptor agonists
- Nicotine
- Varenicline
, tetramethylammonium (TMA, you may use it in a practical) and dimethylphenylpiperazinium (DMPP) are notable but these are not drugs but useful for experiments.
give some nAChRs antagonists: ganglionic blockers
Type 1: agonsits - block tranmission due to sustained depolarisation
type 2: competitive antagonists & channel blockers (eg trimethaphan and hexamethonium)
how does hexamethonium work
blocks the open nAChRs
does hexamethonium show use dependance?
yep
how does trimethephan work?
binds ACh binding site
competitive
very short acting
. The adult Nm is irreversibly antagonised by
α-bungarotoxin (a- BuTx
describe how Depolarizing neuromuscular blocking agents work?
give a main exmaple
bind nAChR
not hydrolyses
hold channel open
fasiculations
phase 1 flaccid paralysis
suxamethonium
describe suxamethonium
effectively a dimer of ACh.
short term paralysis - used to aid tracheal intubation
brocken down by rapid hydrolysis in the plasma by butyrylcholinesterase (BuChE, also known as pseudocholinesterase).
which patietns are at risk from suxamethonium?
rapid hydrolysis of suxamethonium in the plasma by butyrylcholinesterase (BuChE, also known as pseudocholinesterase). This enzyme is synthesized in the liver and patients with liver disease or genetic deficiency of this enzyme therefore run the risk of prolonged action of suxamethonium.
problems associated with depolarising blocking agents?
depolarizing agents causes K+ loss from the muscles (can you predict how?) into blood, which may lead to hyperkalemia and can be life-threatening for some patients, especially if they already suffer from electrolyte imbalance.
describe Non-depolarizing neuromuscular blocking agents
competitive antagonists of the Nm channels i.e. they compete with the endogenous ACh at its binding sites on the Nm channels without stimulating it (hence non-depolarizing). Thus, they prevent depolarization of the sarcolemma and inhibit muscular contraction, leading to a flaccid paralysis
Non-depolarizing neuromuscular blocking agents: are there fasiculations?
nope


